Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults. This type of cancer can be removed with surgery and has not spread to other parts of the body. Both medicines work by helping the immune system fight cancer. The main questions this study wants to answer: How well do the medicines destroy the cancer before surgery? What side effects do participants have when taking the medicines? Researchers will compare two groups to see

Trial Details

NCT ID
NCT07808151
Phase
PHASE2
Sponsor
Solstice Oncology, Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Pembrolizumab
  • Porustobart
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Tampa, Florida, United States|27.94752,-82.45843
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • ≥18 years of age at consent
  • Adenocarcinoma of the colon (rectosigmoid considered non-rectal); pMMR/MSS status
  • Any T3 or T4, N any, M0; disease amenable to surgical resection
  • ECOG Performance Status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →